雲南白藥(000538.SZ):江蘇魚躍減持期屆滿 累計減持1.99997%股份
格隆匯1月16日丨雲南白藥(000538.SZ)公佈,近日,公司收到江蘇魚躍《關於競價減持計劃屆滿暨減持實施進展之自願性信息披露的吿知函》,截至2024年1月13日,上述減持計劃已屆滿,江蘇魚躍已完成本次股份減持計劃,在2023年7月17日至2024年1月13日期間,江蘇魚躍通過集中競價交易累計減持了公司35,936,638股無限售流通股,佔公司總股本1.99997%,減持事項與此前已披露的減持計劃一致,減持數量在減持計劃範圍內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.